Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGR-0320
- Development stage
- Preclinical
- Lead developer
- Schrödinger
- Modality
- Small Molecules
01
Overview
SGR-0320 is a preclinical-stage small molecule inhibitor of Leucine-rich repeat kinase 2 (LRRK2) being developed by Schrodinger for the treatment of neurological disorders. LRRK2 is a large multidomain protein with kinase and GTPase activities; mutations that increase its kinase activity are among the most common genetic risk factors for both familial and sporadic Parkinson's disease. SGR-0320 was identified and optimized using Schrodinger's physics-based computational platform to achieve high potency and selectivity while ensuring the blood-brain barrier penetration necessary for central nervous system activity. The program aims to modulate neurodegenerative pathways implicated in Parkinson's disease and potentially other neurological conditions.
02
Targets
LRRK2 (Leucine-rich repeat serine/threonine-protein kinase 2)
Beyond the preview
Go deeper on SGR-0320.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGR-0320.